Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Borderi

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 20, 2007
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patientsIsabella Bon, Davide Gibellini, Marco Borderi, et al.
The New Microbiologica|February 18, 2014
Prevalence of sub-clinical vertebral fractures in HIV-infected patientsMarco Borderi, Leonardo Calza, Vincenzo Colangeli, et al.
The New Microbiologica|October 31, 2012
Antiretroviral molecules and cardiovascular diseasesDavide Gibellini, Marco Borderi, Alberto Clò, et al.
HIV Research & Clinical Practice|February 18, 2020
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapyLeonardo Calza, Marco Borderi, Bianca Granozzi, et al.
Archives of Neurology|May 22, 2002
Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviorsDiana De Ronchi, Irma Faranca, Domenico Berardi, et al.
Journal of the International AIDS Society|November 14, 2014
Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in ItalyAndrea Antinori, Marco Borderi, Roberto Cauda, et al.
The New Microbiologica|June 4, 2010
Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell lineDavide Gibellini, Marco Borderi, Elisa de Crignis, et al.
Infectious Diseases (London, England)|July 8, 2017
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study)Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patientsLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Current HIV Research|May 19, 2016
Effects of Antiretroviral Molecules on Survival and Gene Expression of An Osteoblast-like Cell LineAnna Miserocchi, Giuseppina Musumeci, Isabella Bon, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 20, 2007
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patientsIsabella Bon, Davide Gibellini, Marco Borderi, et al.
The New Microbiologica|February 18, 2014
Prevalence of sub-clinical vertebral fractures in HIV-infected patientsMarco Borderi, Leonardo Calza, Vincenzo Colangeli, et al.
The New Microbiologica|October 31, 2012
Antiretroviral molecules and cardiovascular diseasesDavide Gibellini, Marco Borderi, Alberto Clò, et al.
HIV Research & Clinical Practice|February 18, 2020
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapyLeonardo Calza, Marco Borderi, Bianca Granozzi, et al.
Archives of Neurology|May 22, 2002
Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviorsDiana De Ronchi, Irma Faranca, Domenico Berardi, et al.
Journal of the International AIDS Society|November 14, 2014
Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in ItalyAndrea Antinori, Marco Borderi, Roberto Cauda, et al.
The New Microbiologica|June 4, 2010
Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell lineDavide Gibellini, Marco Borderi, Elisa de Crignis, et al.
Infectious Diseases (London, England)|July 8, 2017
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study)Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patientsLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Current HIV Research|May 19, 2016
Effects of Antiretroviral Molecules on Survival and Gene Expression of An Osteoblast-like Cell LineAnna Miserocchi, Giuseppina Musumeci, Isabella Bon, et al.
Pageof 7